Litigation over generic drug applications under the Abbreviated New Drug Application process increased 30 percent in 2017, according to a report by litigation analytics company Lex Machina.

The ANDA process accounted for 417 filings in federal courts across the nation in 2017, up from 324 in 2016. But filings of ANDA cases still haven’t reached 2015′s blockbuster level of 475, according to Lex Machina’s report, which was made public Thursday.